5 stories mentioning SHA:603087Updated 25d ago
Every FINWIRES story that references SHA:603087, newest first.
Gan & Lee Pharmaceuticals (SHA:603087) received clinical trial approval from China's drug regulator for GLR2038 tablets to treat advanced breast cancer.The drug, developed on the company's proprietary PROTAC platform, will proceed to monotherapy trials, according to a weekend filing with the Shanghai bourse.Shares of the pharmaceutical company rose 6% Monday.
Honduran authorities approved Gan & Lee Pharmaceuticals' (SHA:603087) insulin glargine injection for diabetes, according to a Monday filing with the Shanghai bourse.The drug is said to have a hypoglycemic effect lasting 24 hours, the company said in its filing.
The European Commission granted Gan & Lee Pharmaceuticals (SHA:603087) marketing authorization for insulin aspart injection Dazparda, according to a Shanghai bourse filing on Thursday.The Chinese pharmaceutical company's unit, Gan & Lee Pharmaceuticals Europe, is the authorized marketer of the product in Europe.The company's shares rose 1% at the close.
Gan & Lee Pharmaceuticals (SHA:603087) received approval from China's National Medical Products Administration for the clinical trials of GLR1062 injection, according to a Shanghai bourse filing on Thursday.The drug will be tested for the treatment of neovascular (wet) age-related macular degeneration in adults.
Gan & Lee Pharmaceuticals' (SHA:603087) subsidiary, Gan & Lee Pharmaceuticals Shandong, dosed the first subject for the phase III clinical trial of GZR33 injection, according to a Shanghai bourse filing on Wednesday.The drug is being tested as a treatment for type 2 diabetes.The pharmaceutical company's shares rose less than 3% during the afternoon trade.
